Erratum: Are circulating metabolites important in drug-drug interactions? Quantitative analysis of risk prediction and inhibitory potency (Clinical Pharmacology and Therapeutics (2011) 89, (105-113) DOI: 10.1038/clpt.2010.252);Are circulating metabolites important in drug-drug interactions: Quantitative analysis of risk prediction and inhibitory potency

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 1, 2011, Pages 105-113

  Yeung, C K ^a   Fujioka, Y ^a   Hachad, H ^a   Levy, R H ^a   Isoherranen, N ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMIODARONE; AMODIAQUINE; ATOMOXETINE; CARBAMAZEPINE; CHLOROQUINE; CITALOPRAM; DESIPRAMINE; DEXTROMETHORPHAN; DRUG METABOLITE; FLUOXETINE; HALOPERIDOL; IMATINIB; IMIPRAMINE; ITRACONAZOLE; METOPROLOL; MEVINOLIN; NIFEDIPINE; OMEPRAZOLE; PIMOZIDE; PROGUANIL; PROPRANOLOL; QUINIDINE; RANOLAZINE; SERTRALINE; SIMVASTATIN; SULFINPYRAZONE; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; DRUG INHIBITION; DRUG POTENCY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RISK ASSESSMENT; STEADY STATE;

EID: 78650513090     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.349     Document Type: Erratum

References (50)

1. Zhang, X., Jones, D.R. & Hall, S.D. Prediction of the efect of erythromycin, Diltiazem, And their metabolites, Alone and in combination, On CyP3a4 inhibition. Drug Metab. Dispos. 37, 150-160 (2009).
2. Zhang, X., Quinney, S.K., Gorski, J.C., Jones, D.R. & Hall, S.D. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab. Dispos. 37, 1587-1597 (2009).
3. Isoherranen, N., Kunze, K.L., Allen, K.E., Nelson, W.L. & Thummel, K.E. Role of itraconazole metabolites in CyP3a4 inhibition. Drug Metab. Dispos. 32, 1121-1131 (2004).
4. Stevens, J.C. & Wrighton, S.A. Interaction of the enantiomers of fuoxetine and norfuoxetine with human liver cytochromes P450. J. Pharmacol. Exp. Ther. 266, 964-971 (1993).
5. Isoherranen, N., Hachad, H., Yeung, C.K. & Levy, R.H. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Chem. Res. Toxicol. 22, 294-298 (2009).
6. Hochman, J.H. et al. Interactions of human P-glycoprotein with simvastatin, Simvastatin acid, And atorvastatin. Pharm. Res. 21, 1686-1691 (2004).
7. Obach, R.S., Walsky, R.L., Venkatakrishnan, K., Houston, J.B. & Tremaine, L.M. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, Quantitative predictions, And the rank-order approach. Clin. Pharmacol. Ther. 78, 582-592 (2005).
8. Brown, H.S., Ito, K., Galetin, A. & Houston, J.B. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br. J. Clin. Pharmacol. 60, 508-518 (2005).
9. Ito, K., Hallifax, D., Obach, R.S. & Houston, J.B. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CyP2D6 paradigm. Drug Metab. Dispos. 33, 837-844 (2005).
10. Robinson, K., Johnston, A., Walker, S., Mulrow, J.P., McKenna, W.J. & Holt, D.W. The digoxin-amiodarone interaction. Cardiovasc. Drugs Ther. 3, 25-28 (1989).
11. Ohyama, K., Nakajima, M., Suzuki, M., Shimada, N., Yamazaki, H. & yokoi, T. Inhibitory efects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br. J. Clin. Pharmacol. 49, 244-253 (2000).
12. Reese, M.J., Wurm, R.M., Muir, K.T., Generaux, G.T., St john-Williams, L. & McConn, D.J. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab. Dispos. 36, 1198-1201 (2008).
13. He, M., Kunze, K.L. & Trager, W.F. Inhibition of (S)-warfarin metabolism by sulfnpyrazone and its metabolites. Drug Metab. Dispos. 23, 659-663 (1995).
14. Otton, S.V., Ball, S.E., Cheung, S.W., Inaba, T., Rudolph, R.L. & Sellers, E.M. Venlafaxine oxidation in vitro is catalysed by CyP2D6. Br. J. Clin. Pharmacol. 41, 149-156 (1996).
15. Jacobsen, W. et al. Lactonization is the critical frst step in the disposition of the 3-hydroxy-3-methylglutaryl-Coa reductase inhibitor atorvastatin. Drug Metab. Dispos. 28, 1369-1378 (2000).
16. Keskitalo, J.E., Kurkinen, K.J., Neuvoneni, P.J. & Niemi, M. ABCB1 haplotypes diferentially afect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin. Pharmacol. Ther. 84, 457-461 (2008).
17. Bapiro, T.E., Egnell, A.C., Hasler, J.A. & Masimirembwa, C.M. Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab. Dispos. 29, 30-35 (2001).
18. Skjelbo, E. & Brøsen, K. Inhibitors of imipramine metabolism by human liver microsomes. Br. J. Clin. Pharmacol. 34, 256-261 (1992).
19. Von Moltke, L.L., Greenblatt, D.J., Cotreau-Bibbo, M.M., Duan, S.X., Harmatz, J.S. & Shader, R.I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, And by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther. 268, 1278-1283 (1994).
20. Prakash, C., Kamel, A., Cui, D., Whalen, R.D., Miceli, J.J. & Tweedie, D. Identifcation of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br. J. Clin. Pharmacol. 49 Suppl 1, 35S-42S (2000).
21. Von Moltke, L.L. et al. Triazolam biotransformation by human liver microsomes in vitro: efects of metabolic inhibitors and clinical confrmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 276, 370-379 (1996).
22. Alderman, J. Coadministration of sertraline with cisapride or pimozide: an open-label, Nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. Clin. Ther. 27, 1050-1063 (2005).
23. Shin, J.G., Kane, K. & Flockhart, D.A. Potent inhibition of CyP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br. J. Clin. Pharmacol. 51, 45-52 (2001).
24. Otton, S.V., Wu, D., Jofe, R.T., Cheung, S.W. & Sellers, E.M. Inhibition by fuoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther. 53, 401-409 (1993). (Pubitemid 23119426)
25. Kobayashi, K., Yamamoto, T., Chiba, K., Tani, M., Ishizaki, T. & Kuroiwa, Y. The efects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes. Br. J. Clin. Pharmacol. 40, 481-485 (1995).
26. Rowland, K. et al. Inhibition of CyP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol. Br. J. Clin. Pharmacol. 38, 9-14 (1994).
27. Crespi, C.L. & Penman, B.W. Use of cDNa-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv. Pharmacol. 43, 171-188 (1997).
28. Masimirembwa, C.M., Hasler, J.A. & johansson, I. Inhibitory efects of antiparasitic drugs on cytochrome P450 2D6. Eur. J. Clin. Pharmacol. 48, 35-38 (1995).
29. Wang, Y. et al. Efects of imatinib (Glivec) on the pharmacokinetics of metoprolol, A CyP2D6 substrate, In Chinese patients with chronic myelogenous leukaemia. Br. J. Clin. Pharmacol. 65, 885-892 (2008).
30. Lakehal, F., Wurden, C.J., Kalhorn, T.F. & Levy, R.H. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CyP2C19. Epilepsy Res. 52, 79-83 (2002).
31. Sauer, J.M. et al. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J. Pharmacol. Exp. Ther. 308, 410-418 (2004).
32. Chiba, K., Kobayashi, K., Manabe, K., Tani, M., Kamataki, T. & Ishizaki, T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. J. Pharmacol. Exp. Ther. 266, 52-59 (1993).
33. Zomorodi, K. & Houston, J.B. Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. Br. J. Clin. Pharmacol. 42, 157-162 (1996).
34. Ching, M.S. et al. Potent inhibition of yeast-expressed CyP2D6 by dihydroquinidine, Quinidine, And its metabolites. Biochem. Pharmacol. 50, 833-837 (1995).
35. O'Reilly, R.A., Trager, W.F., Rettie, A.E. & Goulart, D.A. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin. Pharmacol. Ther. 42, 290-294 (1987).
36. Shoaf, S.E. et al. Tolvaptan administration does not afect steady state amiodarone concentrations in patients with cardiac arrhythmias. J. Cardiovasc. Pharmacol. Ther. 10, 165-171 (2005).
37. Bergstrom, R.F., Peyton, A.L. & Lemberger, L. Quantifcation and mechanism of the fuoxetine and tricyclic antidepressant interaction. Clin. Pharmacol. Ther. 51, 239-248 (1992).
38. Harvey, A.T. & Preskorn, S.H. Fluoxetine pharmacokinetics and efect on CyP2C19 in young and elderly volunteers. J. Clin. Psychopharmacol. 21, 161-166 (2001).
39. Neuvonen, P.J. & jalava, K.M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 60, 54-61 (1996).
40. Funck-Brentano, C., Becquemont, L., Lenevu, A., Roux, A., Jaillon, P. & Beaune, P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J. Pharmacol. Exp. Ther. 280, 730-738 (1997).
41. Stuht, H., Lode, H., Koeppe, P., Rost, K.L. & Schaberg, T. Interaction study of lomefoxacin and ciprofoxacin with omeprazole and comparative pharmacokinetics. Antimicrob. Agents Chemother. 39, 1045-1049 (1995).
42. Soons, P.A. et al. Infuence of single-and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and efects in healthy subjects. Eur. J. Clin. Pharmacol. 42, 319-324 (1992).
43. Capon, D.A., Bochner, F., Kerry, N., Mikus, G., Danz, C. & Somogyi, A.A. The infuence of CyP2D6 polymorphism and quinidine on the disposition and antitussive efect of dextromethorphan in humans. Clin. Pharmacol. Ther. 60, 295-307 (1996).
44. Damkier, P., Hansen, L.L. & Brosen, K. Efect of diclofenac, Disulfram, Itraconazole, Grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br. J. Clin. Pharmacol. 48, 829-838 (1999).
45. Kurtz, D.L., Bergstrom, R.F., Goldberg, M.J. & Cerimele, B.J. The efect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin. Pharmacol. Ther. 62, 145-156 (1997).
46. Alderman, J. et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J. Clin. Psychopharmacol. 17, 284-291 (1997).
47. O'Reilly, R.A. Stereoselective interaction of sulfnpyrazone with racemic warfarin and its separated enantiomorphs in man. Circulation 65, 202-207 (1982).
48. Rosenkranz, B., Fischer, C., Jakobsen, P., Kirstein Pedersen, A. & Frölich, J.C. Plasma levels of sulfnpyrazone and of two of its metabolites after a single dose and during the steady state. Eur. J. Clin. Pharmacol. 24, 231-235 (1983).
49. Albers, L.J. et al. Efect of venlafaxine on imipramine metabolism. Psychiatry Res. 96, 235-243 (2000).
50. Lindh, J.D., Annas, A., Meurling, L., Dahl, M.L. & aL-Shurbaji, A. Efect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur. J. Clin. Pharmacol. 59, 401-406 (2003).